- Home
- NPWR vs TVRD Comparison
NPWR vs TVRD Comparison
Compare NPWR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- TVRD
- Stock Information
- Founded
- NPWR 2010
- TVRD 2017
- Country
- NPWR United States
- TVRD United States
- Employees
- NPWR N/A
- TVRD N/A
- Industry
- NPWR Industrial Machinery/Components
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- NPWR Energy
- TVRD Health Care
- Exchange
- NPWR Nasdaq
- TVRD Nasdaq
- Market Cap
- NPWR 148.7M
- TVRD 166.5M
- IPO Year
- NPWR N/A
- TVRD N/A
- Fundamental
- Price
- NPWR $1.91
- TVRD $25.61
- Analyst Decision
- NPWR Buy
- TVRD Strong Buy
- Analyst Count
- NPWR 2
- TVRD 1
- Target Price
- NPWR $4.00
- TVRD $39.00
- AVG Volume (30 Days)
- NPWR 593.5K
- TVRD 39.1K
- Earning Date
- NPWR 05-12-2025
- TVRD 05-21-2025
- Dividend Yield
- NPWR N/A
- TVRD N/A
- EPS Growth
- NPWR N/A
- TVRD N/A
- EPS
- NPWR N/A
- TVRD N/A
- Revenue
- NPWR $250,000.00
- TVRD N/A
- Revenue This Year
- NPWR $308.00
- TVRD N/A
- Revenue Next Year
- NPWR $1,811.08
- TVRD N/A
- P/E Ratio
- NPWR N/A
- TVRD N/A
- Revenue Growth
- NPWR 42.86
- TVRD N/A
- 52 Week Low
- NPWR $1.62
- TVRD $8.14
- 52 Week High
- NPWR $14.28
- TVRD $31.32
- Technical
- Relative Strength Index (RSI)
- NPWR 37.16
- TVRD N/A
- Support Level
- NPWR $1.79
- TVRD N/A
- Resistance Level
- NPWR $1.93
- TVRD N/A
- Average True Range (ATR)
- NPWR 0.14
- TVRD 0.00
- MACD
- NPWR 0.12
- TVRD 0.00
- Stochastic Oscillator
- NPWR 64.77
- TVRD 0.00
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.